A marker for breast cancer diagnosis and its screening method
A marker, breast cancer technology, applied in the direction of biochemical equipment and methods, microbial determination/examination, DNA/RNA fragments, etc., can solve the problem of low sensitivity of early breast cancer detection, and unsatisfactory sensitivity and specificity of early diagnosis And other issues
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0031] 1. Target tRF&tiRNA screening
[0032] 1) Tissue specimens (cancer and paracancerous) of 6 breast cancer patients were obtained from the biobank, and the Agilent BioAnalyzer 2100 (Agilent BioAnalyzer 2100) library preparation, Illumina NextSeq 500 high-throughput desktop next-generation sequencing system and high-throughput sequencing were used. Gene Expression Omnibus big data analysis screened tRFs & tiRNAs, the results showed that there were 1135 tRFs & tiRNAs differentially expressed by more than 2 times in tissues (496 up-regulated and 639 down-regulated, such as figure 2 shown);
[0033] 2) According to the difference fold FC (Fold change)>2, P image 3 shown);
[0034] 3) With FC>2.5, P<0.05, combined with Gene Ontology functional enrichment analysis (Gene Ontology functional enrichment analysis) and Kyoto Encyclopedia of Genes and Genomes pathway analysis (Kyoto Encyclopedia of Genes and Genomes pathway analysis) and breast cancer correlation Literature search...
Embodiment 2
[0046] 1. Target tRF&tiRNA screening
[0047] 1) Tissue specimens (cancer and adjacent cancer) of 6 breast cancer patients were obtained from the biobank, and the Agilent BioAnalyzer 2100 (Agilent BioAnalyzer 2100) library preparation, Illumina NextSeq 500 high-throughput desktop next-generation sequencing system and high-throughput sequencing were used. Gene Expression Omnibus big data analysis screened tRFs&tiRNAs, the results showed that there were 1135 tRFs&tiRNAs differentially expressed by more than 2 times in tissues (496 up-regulated and 639 down-regulated, such as figure 2 shown);
[0048] 2) According to the difference fold FC (Fold change)>2, P image 3 shown);
[0049] 3) With FC>2.5, P<0.05, combined with Gene Ontology functional enrichment analysis (Gene Ontology functional enrichment analysis) and Kyoto Encyclopedia of Genes and Genomes pathway analysis (Kyoto Encyclopedia of Genes and Genomes pathway analysis) and breast cancer correlation Literature search, ...
Embodiment 3
[0062] 1. Target tRF&tiRNA screening
[0063] 1) Tissue specimens (cancer and adjacent cancer) of 6 breast cancer patients were obtained from the biobank, and the Agilent BioAnalyzer 2100 (Agilent BioAnalyzer 2100) library preparation, Illumina NextSeq 500 high-throughput desktop next-generation sequencing system and high-throughput sequencing were used. Gene Expression Omnibus big data analysis screened tRFs&tiRNAs, the results showed that there were 1135 tRFs&tiRNAs differentially expressed by more than 2 times in tissues (496 up-regulated and 639 down-regulated, such as figure 2 shown);
[0064] 2) According to the difference fold FC (Fold change)>2, P image 3 shown);
[0065] 3) FC>2.5, P<0.05, combined with Gene Ontology functional enrichment analysis (Gene Ontology functional enrichment analysis) and Kyoto Encyclopedia of Genes and Genomes pathway analysis (Kyoto Encyclopedia of Genes and Genomes pathway analysis) and breast cancer related literature After searching, ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


